TABLE 3.
Diagnostic performance of the Aspergillus IgG LFA in CPA cohorta
| Test group | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV (95% CI) | NPV (95% CI) | Youden’s index (95% CI) |
|---|---|---|---|---|---|
| Non-CPAb (n = 55) | - | 92.7 (82.4–98.0) | - | - | - |
| CPA (n = 126) | 55.6 (46.4–64.4) | 0.95 (0.87–0.99) | 0.48 (0.38–0.58) | 0.48 (0.29–0.62) | |
| A. fumigatus cases (n = 39) | 87.2 (72.6–95.7) | 0.89 (0.75–0.97) | 0.91 (0.80–0.97) | 0.80 (0.55–0.94) | |
| non-A. fumigatus cases (n = 12) | 8.3 (0.2–38.5) | 0.20 (0.01–0.72) | 0.82 (0.70–0.91) | 0.01 (−0.17−0.36) | |
| CCPAc (n = 61) | 75.4 (62.7–85.5) | 0.92 (0.81–0.98) | 0.77 (0.65–0.87) | 0.68 (0.45–0.84) | |
| CNPA (n = 20) | 55.0 (31.5–76.9) | 0.73 (0.45–0.92) | 0.85 (0.73–0.93) | 0.47 (0.14–0.75) | |
| SA (n = 12) | 25.0 (5.5–57.2) | 0.43 (0.10–0.86) | 0.85 (0.73–0.93) | 0.18 (−0.12−0.55) | |
| AN (n = 33) | 30.3 (15.6–48.7) | 0.71 (0.42–0.92) | 0.69 (0.57–0.79) | 0.23 (−0.02−0.47) |
LFA, lateral flow assay; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; CPA, chronic pulmonary aspergillosis; CCPA, chronic cavitary pulmonary aspergillosis; CFPA, chronic fibrosing pulmonary aspergillosis; CNPA, chronic necrotizing pulmonary aspergillosis; SA, simple aspergilloma; AN, Aspergillus nodule.
Non-CPA controls included diseased patients with cryptococcosis (n = 27), mucormycosis (n = 9), mycobacterial lung disease (n = 5), lung cancer (n = 4), nocardiosis (n = 3), penicilliosis (n = 2), histoplasmosis (n = 2), chromomycosis (n = 1), coccidioidomycosis (n = 1), and actinomycosis (n = 1).
Two patients diagnosed with CFPA were included.